Relmada Therapeutics (RLMD) 10-Q 5 May 22 2022 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2022	May 02, 2022
Document Information Line Items
Entity Registrant Name	RELMADA THERAPEUTICS, INC.
Trading Symbol	RLMD
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		29,990,790
Amendment Flag	false
Entity Central Index Key	0001553643
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Mar. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	000-55347
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	45-5401931
Entity Address, Address Line One	2222 Ponce de Leon
Entity Address, Address Line Two	Floor 3
Entity Address, City or Town	Coral Gables
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33134
City Area Code	(786)
Local Phone Number	629-1376
Title of 12(b) Security	Common stock, $0.001 par value per share
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 44,934,376	$ 44,443,439
Short-term investments	175,715,526	167,466,167
Lease payments receivable – short term	65,454	86,377
Prepaid expenses	5,063,960	11,301,535
Total current assets	225,779,316	223,297,518
Other assets	28,293	28,293
Total assets	225,807,609	223,325,811
Commitments and Contingencies (See Note 7)
Current liabilities:
Accounts payable	10,670,149	11,192,502
Accrued expenses	4,739,328	3,868,423
Total current liabilities	15,409,477	15,060,925
Total liabilities	15,409,477	15,060,925
Stockholders’ Equity:
Class A convertible preferred stock, $0.001 par value, 3,500,000 shares authorized, none issued and outstanding
Common stock, $0.001 par value, 50,000,000 shares authorized, 29,402,824 and 27,740,147 shares issued and outstanding, respectively	29,403	27,740
Additional paid-in capital	555,181,624	513,304,258
Accumulated deficit	(344,812,895)	(305,067,112)
Total stockholders’ equity	210,398,132	208,264,886
Total liabilities and stockholders’ equity	$ 225,807,609	$ 223,325,811

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	29,402,824	27,740,147
Common stock, shares outstanding	29,402,824	27,740,147
Class A convertible preferred stock [Member]
Preferred stock par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	3,500,000	3,500,000
Preferred stock, shares issued
Preferred stock, shares outstanding

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating expenses:
Research and development	$ 25,012,853	$ 14,022,227
General and administrative	13,284,570	8,382,976
Total operating expenses	38,297,423	22,405,203
Loss from operations	(38,297,423)	(22,405,203)
Other (expenses) income:
Interest/investment income, net	329,949	419,974
Realized loss on short-term investments	(15,022)	(52,789)
Unrealized loss on short-term investments	(1,763,287)	(177,163)
Total other (expense) income	(1,448,360)	190,022
Net loss	$ (39,745,783)	$ (22,215,181)
Loss per common share – basic and diluted (in Dollars per share)	$ (1.4)	$ (1.34)
Weighted average number of common shares outstanding – basic and diluted (in Shares)	28,392,601	16,572,672

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2020	$ 16,333	$ 284,881,716	$ (179,315,303)	$ 105,582,746
Balance (in Shares) at Dec. 31, 2020	16,332,939
Stock based compensation		5,851,284		5,851,284
Warrant exercised for cash	$ 33	299,973		300,006
Warrant exercised for cash (in Shares)	33,334
Options exercised for cash	$ 20	64,780		64,800
Options exercised for cash (in Shares)	20,000
Net loss			(22,215,181)	(22,215,181)
Balance at Mar. 31, 2021	$ 16,748	292,660,864	(201,530,484)	91,147,128
Balance (in Shares) at Mar. 31, 2021	16,748,055
Balance at Dec. 31, 2021	$ 27,740	513,304,258	(305,067,112)	208,264,886
Balance (in Shares) at Dec. 31, 2021	27,740,147
Stock based compensation		11,930,681		11,930,681
ATM offering, net	$ 1,610	29,581,932		29,583,542
ATM offering, net (in Shares)	1,609,343
Warrant exercised for cash	$ 273	1,460,233		1,460,506
Warrant exercised for cash (in Shares)	273,491
Options exercised for cash	$ 142	467,631		467,773
Options exercised for cash (in Shares)	141,625
Net loss			(39,745,783)	(39,745,783)
Balance at Mar. 31, 2022	$ 29,403	$ 555,181,624	$ (344,812,895)	$ 210,398,132
Balance (in Shares) at Mar. 31, 2022	29,402,824

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities
Net loss	$ (39,745,783)	$ (22,215,181)
Depreciation expense		806
Stock-based compensation	11,930,681	5,851,284
Realized loss on short-term investments	15,022	52,789
Unrealized loss on short-term investments	1,763,287	177,163
Change in operating assets and liabilities:
Lease payment receivable	20,923	19,247
Prepaid expenses	6,237,575	(87,505)
Accounts payable	(522,353)	(263,679)
Accrued expenses	870,905	379,601
Net cash used in operating activities	(19,429,743)	(16,085,475)
Cash flows from investing activities
Purchase of short-term investments	(25,915,957)	(20,663,535)
Sale of short-term investments	15,888,289	36,129,376
Net cash (used in) provided by investing activities	(10,027,668)	15,465,841
Cash flows from financing activities
Proceeds from issuance of common stock	29,583,542
Proceeds from options exercised for common stock	64,800	467,773
Proceeds from warrants exercised for common stock	300,006	1,460,506
Net cash provided by financing activities	29,948,348	1,928,279
Net increase in cash and cash equivalents	490,937	1,308,645
Cash and cash equivalents at beginning of the period	44,443,439	2,495,397
Cash and cash equivalents at end of the period	44,934,376	3,804,042
Cash paid during the period for:
Income taxes
Interest

Business

Business	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
BUSINESS	NOTE 1 - BUSINESS Relmada Therapeutics, Inc. (Relmada or the Company) (a Nevada corporation), is a clinical-stage, publicly traded biotechnology company focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone is a New Chemical Entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. In addition to the normal risks associated with a new business venture, there can be no assurance that the Company’s research and development will be successfully completed or that any product will be approved or commercially viable. The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, dependence on collaborative arrangements, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with the Food and Drug Administration (FDA) and other governmental regulations and approval requirements.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim unaudited condensed consolidated financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete consolidated financial statements. The unaudited condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements of the Company for the year ended December 31, 2021 and notes thereto contained in the Company’s Annual Report on Form 10-K. Liquidity As shown in the accompanying unaudited condensed consolidated financial statements, the Company incurred negative operating cash flows of $19,429,743 for the three months ended March 31, 2022 and has an accumulated deficit of $344,812,895 from inception through March 31, 2022. Relmada has funded its past operations through equity raises and most recently in the three months ended March 31, 2022, the Company raised net proceeds of $29,583,542 from the sale of common stock through our at-the-market (ATM) equity offering, $64,800 through the exercise of options and $300,006 through the exercise of warrants. Management believes that the Company’s existing cash and cash equivalents will enable it to fund operating expenses and capital expenditure requirements for at least 12 months from the issuance of these unaudited condensed consolidated financial statements. Beyond that point management will evaluate the size and scope of any subsequent trials that will affect the timing of additional financings through public or private sales of equity or debt securities or from bank or other loans or through strategic collaboration and/or licensing agreements. Any such expenditures related to any subsequent clinical trials will not be incurred until such additional financing is raised. Further, additional financing related to subsequent clinical trials does not affect the Company’s conclusion that based on the cash on hand and the budgeted cash flow requirements, the Company has sufficient funds to maintain operations for at least 12 months from the issuance of these unaudited condensed consolidated financial statements. Principles of Consolidation The unaudited condensed consolidated financial statements include the Company’s accounts and those of the Company’s wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation. Risks and Uncertainties The ongoing pandemic may adversely affect our business. Based on the Company’s current assessment, the Company does not expect any material impact on its long-term development timeline and its liquidity due to the worldwide spread of the coronavirus (COVID-19). However, the Company is actively monitoring this situation and the possible effects on its financial condition, liquidity, operations, suppliers, industry, and workforce. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates. The significant estimates are stock-based compensation expenses and recorded amounts related to income taxes. Cash and Cash Equivalents The Company considers cash deposits and all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company’s cash deposits are held at two high-credit-quality financial institutions. The Company’s cash and cash equivalents at these institutions exceed federally insured limits. The Company’s cash balance of $44,934,376 at March 31, 2022 at these institutions exceed the federally insured limits. Short-term Investments The Company’s investments consist entirely of mutual funds. The securities are measured at fair value based on the net asset value (NAV). Substantially all equity investments in nonconsolidated entities are measured at fair value with recurring changes recognized in earnings, except for those accounted for using equity method accounting. Changes in fair value of the securities are recorded as part of other income on the condensed consolidated statement of operations. Short term investment activity is presented in the investing activities section on the condensed consolidated statement of cash flows. Short-term investments at March 31, 2022 consisted of mutual funds with a fair value of $175,715,526. Patents Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain. Leases The Company recognizes its leases with a term of greater than a year on the balance sheet by recording right-of-use assets and lease liabilities. Leases can be classified as either operating leases or finance leases. Operating leases will result in straight-line lease expense, while finance leases will result in front-loaded expense. The Company’s lease consists of an operating lease for office space. The Company does not recognize a lease liability or right-of-use asset on the balance sheet for short-term leases. Instead, the Company recognizes short-term lease payments as an expense on a straight-line basis over the lease term. A short-term lease is defined as a lease that, at the commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise. Fair Value of Financial Instruments The Company’s financial instruments primarily include cash, short term investments, and accounts payable. Due to the short-term nature of cash and accounts payable the carrying amounts of these assets and liabilities approximate their fair value. Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability (an exit price), in an orderly transaction between market participants at the reporting date. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows: Level 1 Inputs - Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 2 Inputs - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means. Level 3 Inputs - Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity). As required by Accounting Standard Codification (ASC) Topic No. 820 - 10 Fair Value Measurement The Company’s short-term investment instruments of $175,715,526 at March 31, 2022 consist of mutual funds, bank deposits and money market funds and are classified using Level 1 inputs within the fair value hierarchy because the value is based on quoted prices in active markets. Unrealized gains and losses are recorded in the condensed consolidated statement of operations under other income. The Company recorded unrealized losses of $1,763,287 and $177,163 included in other income for the three months ended March 31, 2022 and 2021, respectively. Income Taxes The Company accounts for income taxes using the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in the tax rate is recognized in income or expense in the period that the change is effective. Tax benefits are recognized when it is probable that the deduction will be sustained. A valuation allowance is established when it is more likely than not that all or a portion of a deferred tax asset will either expire before the Company is able to realize the benefit, or that future deductibility is uncertain. As of March 31, 2022 and December 31, 2021, the Company had recognized a valuation allowance to the full extent of the Company’s net deferred tax assets since the likelihood of realization of the benefit does not meet the more likely than not threshold. The Company files a U.S. Federal income tax return and various state returns. Uncertain tax positions taken on the Company’s tax returns will be accounted for as liabilities for unrecognized tax benefits. The Company will recognize interest and penalties, if any, related to unrecognized tax benefits in general and administrative expenses in the statements of operations. There were no liabilities recorded for uncertain tax positions at March 31, 2022 and December 31, 2021. The open tax years, subject to potential examination by the applicable taxing authority, for the Company are from June 30, 2018 forward. Research and Development Research and development costs primarily consist of research contracts for the advancement of product development, salaries and benefits, stock-based compensation, and consultants. The Company expenses all research and development costs in the period incurred. The Company makes an estimate of costs in relation to clinical study contracts. The Company analyzes the progress of studies, including the progress of clinical studies and phases, invoices received and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability. Stock-Based Compensation The Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the period during which an employee is required to provide service in exchange for the award - the requisite service period. The grant-date fair value of employee share options is estimated using the Black-Scholes option pricing model adjusted for the unique characteristics of those instruments. Net Loss per Common Share Basic loss per common share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted loss per common share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of options and warrants to purchase common stock. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net losses in each period. For the three months ended March 31, 2022 and 2021, the potentially dilutive securities that would be anti-dilutive due to the Company’s net loss are not included in the calculation of diluted net loss per share attributable to common stockholders. The anti-dilutive securities are as follows (in common stock equivalent shares): Three months ended March 31, March 31, Stock options 10,262,184 5,165,987 Common stock warrants 3,175,443 2,797,142 Total 13,437,627 7,963,129 Recent Accounting Pronouncements In November 2021, the FASB issued ASU 2021-10, “ Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance In October 2021, the FASB issued ASU 2021-08, “ Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes In May 2021, the FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) Subsequent Events The Company’s management reviewed all material events through the date the financial statements were issued for subsequent event disclosure consideration.

Prepaid Expenses

Prepaid Expenses	3 Months Ended
	Mar. 31, 2022
Prepaid Expenses [Abstract]
PREPAID EXPENSES	NOTE 3 - PREPAID EXPENSES Prepaid expenses consisted of the following (rounded to nearest $00): March 31, December 31, Insurance $ 164,600 $ 353,300 Research and Development 4,743,700 10,708,800 Legal 11,000 11,000 Other 144,700 228,400 Total $ 5,064,000 $ 11,301,500

Accrued Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2022
Payables and Accruals [Abstract]
ACCRUED EXPENSES	NOTE 4 - ACCRUED EXPENSES Accrued expenses consisted of the following (rounded to nearest $00): March 31, December 31, Research and development $ 3,585,200 $ 1,928,000 Professional fees 113,700 168,000 Accrued bonus 422,700 1,191,000 Accrued vacation 503,500 450,400 Other 114,200 131,000 Total $ 4,739,300 $ 3,868,400

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2022
Stockholders' Equity Note [Abstract]
STOCKHOLDERS' EQUITY	NOTE 5 - STOCKHOLDERS’ EQUITY Common Stock During the three months ended March 31, 2022, the Company issued 33,334 shares of common stock for cash exercises of warrants for proceeds of $300,006. During the three months ended March 31, 2022, the Company issued 20,000 shares of common stock for the exercise of options for proceeds of $64,800. On May 15, 2020, the Company entered into an Open Market Sale Agreement with Jefferies LLC, as sales agent (“Jefferies”), pursuant to which the Company may offer and sell, from time to time, through Jefferies, shares of the Company’s common stock, having an aggregate offering price of up to $75,000,000. The Company was not obligated to sell any shares under the agreement. During the three months ended March 31, 2022, the Company issued 1,609,343 shares of common stock for net cash proceeds of $29,583,542 under the agreement. Options and Warrants In December 2014, the Board of Directors adopted and the Company’s shareholders approved Relmada’s 2014 Stock Option and Equity Incentive Plan, as amended (the “Plan”), which allows for the granting of 5,152,942 common stock awards, stock appreciation rights, and incentive and nonqualified stock options to purchase shares of the Company’s common stock to designated employees, non-employee directors, and consultants and advisors. In May 2021, the Company’s Board of Directors adopted and shareholders approved Relmada’s 2021 Equity Incentive Plan which allows for the granting of 1,500,000 options or stock awards. These combined plans allow for the granting of up to 6,652,942 options or stock awards. Stock options are exercisable generally for a period of 10 years from the date of grant and generally vest over four years. As of March 31, 2022, no shares were available for future grants under the Plan. The shareholders will vote at their annual meeting in 2022 on a management proposal to increase the shares available to be issued under the 2021 Plan by 3,900,000 shares; there can be no assurance such amendment will be approved. As of March 31, 2022, options for 3,609,242 shares of common stock had been issued subject to approval by the shareholders of this amendment. If the amendment is not approved, such options will be forfeited. As of March 31, 2022, no stock appreciation rights have been issued. The Company utilizes the Black-Scholes option pricing model to estimate the fair value of stock options and warrants. The risk-free interest rate assumptions were based upon the observed interest rates appropriate for the expected term of the equity instruments. The expected dividend yield was assumed to be zero as the Company has not paid any dividends since its inception and does not anticipate paying dividends in the foreseeable future. The expected volatility was based on historical volatility. The Company routinely reviews its calculation of volatility changes in future volatility, the Company’s life cycle, its peer group, and other factors. The Company uses the simplified method for share-based compensation to estimate the expected term for equity awards for share-based compensation in its option-pricing model. On January 1, 2022, 50,000 options were issued to a consultant with an exercise price of $22.53 From January 1, 2022 through March 14, 2022, 110,000 options were issued to various consultants with an exercise price ranging from $18.00 to $21.46 On March 28, 2022, the Company awarded a total of 15,000 options to an employee with an exercise price of $25.76 and a 10-year term vesting over a 4-year period. The options granted include time-based vesting grants. The options have an aggregate fair value of $307,845 calculated using the Black Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: At March 31, 2022, the Company has unrecognized stock-based compensation expense of approximately $129.7 million related to unvested stock options over the weighted average remaining service period of 2.72 years. Options A summary of the changes in options during the three months ended March 31, 2022 is as follows: Number of Weighted Weighted Aggregate Outstanding and expected to vest at December 31, 2021 10,330,622 $ 22.52 9.00 $ 46,088,534 Granted 175,000 $ 20.35 9.84 $ - Exercised (20,000 ) $ 3.24 - $ - Forfeited (223,438 ) $ 27.22 - $ - Outstanding at March 31, 2022 10,262,184 $ 22.42 8.79 $ 78,393,636 Options exercisable at March 31, 2022 2,748,859 $ 21.56 7.42 $ 29,334,704 Warrants A summary of the changes in outstanding warrants during the three months ended March 31, 2022 is as follows: Number of Weighted Outstanding and vested at December 31, 2021 3,208,777 $ 16.45 Granted - $ - Exercised (33,334 ) $ 9.00 Outstanding at March 31, 2022 3,175,443 $ 16.53 Warrants Vested at March 31, 2022 2,799,693 $ 14.40 At March 31, 2022, the Company had approximately $8.6 million of unrecognized compensation expense related to outstanding warrants. At March 31, 2022, the aggregate intrinsic value of warrants vested and outstanding was approximately $39.6 million. Stock -based compensation by class of expense The following table summarizes the components of stock-based compensation expense which includes stock options and warrants in the unaudited consolidated statements of operations for the three months ended March 31, 2022 and 2021 (rounded to nearest $00): Three Three Research and development $ 1,258,400 $ 545,800 General and administrative 10,672,300 5,305,500 Total $ 11,930,700 $ 5,851,300

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2022
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 6 - RELATED PARTY TRANSACTIONS Effective March 6, 2020, Dr. Ottavio Vitolo, the Company’s Chief Medical Officer and Head of Research and Development, entered into a Separation and Severance Agreement with the Company. Pursuant to the terms of the agreement, the Company agreed to pay Dr. Vitolo severance of $200,000 in accordance with his employment contract. In addition, Dr. Vitolo’s options granted under the Company’s 2014 Stock Option and Equity Incentive Plan continued to vest until September 6, 2020. Dr. Vitolo had until March 6, 2021 to exercise his vested options and was allowed to use a cashless exercise provision to exercise his vested options. Dr. Vitolo exercised 126,562 options during 2020 and the remaining options expired on March 6, 2021. The agreement also contains customary confidentiality, release, and non-disparagement provisions, and the Company paid accrued and unpaid salary, vacation time and attorney’s fees totaling approximately $45,000. Effective December 31, 2020, Dr. Thomas Wessel, the Company’s Executive Vice President, Head of Research and Development, entered into a Separation and Severance Agreement with the Company. Pursuant to the terms of the agreement, the Company agreed to pay Dr. Wessel severance of $237,500 in accordance with his employment contract. In addition, Dr. Wessel’s options granted under the Company’s 2014 Stock Option and Equity Incentive Plan continue to vest until June 30, 2021. Dr. Wessel shall have until December 31, 2021 to exercise his vested options and he shall be allowed to use a cashless exercise provision to exercise his vested options. All of Dr. Wessel’s options expired on December 31, 2021. The agreement also contains customary confidentiality, release, and non-disparagement provisions, and the Company paid accrued vacation time totaling approximately $28,940.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 7 - COMMITMENTS AND CONTINGENCIES License Agreements Wonpung On August 20, 2007, the Company entered into a License Development and Commercialization Agreement with Wonpung Mulsan Co, a shareholder of the Company. Wonpung has exclusive territorial rights in countries it selects in Asia to market up to two drugs the Company was developing at the time of the signing of the agreement and a right of first refusal (ROFR) for up to an additional five drugs that the Company may develop in the future as defined in more detail in the license agreement. If the parties cannot agree to terms of a license agreement then the Company shall be able to engage in discussions with other potential licensors. As of March 31, 2022, no discussions are active between the Company and Wonpung. The Company received an upfront license fee of $1,500,000 and will earn royalties of up to 12% of net sales for up to two licensed products it was developing at the time of the signing of the agreement. The licensing terms for the ROFR products are subject to future negotiations and binding arbitration. The terms of each licensing agreement will expire on the earlier of any time from 15 years to 20 years after licensing or on the date of commercial availability of a generic product to such licensed product in the licensed territory. Third Party Licensor Based upon a prior acquisition, the Company assumed an obligation to pay third parties (Dr. Charles E. Inturrisi and Dr. Paolo Manfredi – see below): (A) royalty payments up to 2% on net sales of licensed products that are not sold by sublicensee and (B) on each and every sublicense earned royalty payment received by licensee from its sublicensee on sales of license product by sublicensee, the higher of (i) 20% of the royalties received by licensee; or (ii) up to 2% of net sales of sublicensee. The Company will also make milestone payments of up to $4 or $2 million, for the first commercial sale of product in the field that has a single active pharmaceutical ingredient, and for the first commercial sale of product in the field of product that has more than one active pharmaceutical ingredient, respectively. As of March 31, 2022, the Company has not generated any revenue related to this license agreement. Inturrisi / Manfredi In January 2018, we entered into an Intellectual Property Assignment Agreement (the Assignment Agreement) and License Agreement (the License Agreement and together with the Assignment Agreement, the Agreements) with Dr. Charles E. Inturrisi and Dr. Paolo Manfredi (collectively, the Licensor). Pursuant to the Agreements, Relmada assigned its existing rights, including patents and patent applications, to esmethadone in the context of psychiatric use (the Existing Invention) to Licensor. Licensor then granted Relmada under the License Agreement a perpetual, worldwide, and exclusive license to commercialize the Existing Invention and certain further inventions regarding esmethadone in the context of other indications such as those contemplated above. In consideration of the rights granted to Relmada under the License Agreement, Relmada paid the Licensor an upfront, non-refundable license fee of $180,000. Additionally, Relmada will pay Licensor $45,000 every three months until the earliest to occur of the following events: (i) the first commercial sale of a licensed product anywhere in the world, (ii) the expiration or invalidation of the last to expire or be invalidated of the patent rights anywhere in the world, or (iii) the termination of the License Agreement. Relmada will also pay Licensor tiered royalties with a maximum rate of 2%, decreasing to 1.75%, and 1.5% in certain circumstances, on net sales of licensed products covered under the License Agreement. Relmada will also pay Licensor tiered payments up to a maximum of 20%, and decreasing to 17.5%, and 15% in certain circumstances, of all consideration received by Relmada for sublicenses granted under the License Agreement. As of March 31, 2022, no events have occurred, and the Company continues to pay Licensor $45,000 every three months. Arbormentis, LLC On July 16, 2021, the Company entered into a License Agreement with Arbormentis, LLC, a privately held Delaware limited liability company, by which the Company acquired development and commercial rights to a novel psilocybin and derivate program from Arbormentis, LLC, worldwide excluding the countries of Asia. The Company will collaborate with Arbormentis, LLC on the development of new therapies targeting neurological and psychiatric disorders, leveraging its understanding of neuroplasticity, and focusing on this emerging new class of drugs targeting the neuroplastogen mechanism of action. Under the terms of the License Agreement, the Company paid Arbormentis, LLC an upfront fee of $12.7 million, consisting of a mix of cash and warrants to purchase the Company’s common stock, in addition to potential milestone payments totaling up to approximately $160 million related to pre-specified development and commercialization milestones. Arbormentis, LLC is also eligible to receive a low single digit royalty on net sales of any commercialized therapy resulting from this agreement. The license agreement is terminable by the Company but is perpetual and not terminable by the licensor absent material breach of its terms by the Company. The new licensed program stems from an international collaboration among U.S., European and Swiss scientists that has focused on the discovery and development of compounds that may promote neural plasticity. Dr. Paolo Manfredi, Relmada’s Acting Chief Scientific Officer and co-inventor of REL-1017, and Dr. Marco Pappagallo, Relmada’ s Acting Chief Medical Officer, are among the scientists affiliated with Arbormentis, LLC. Legal From time to time, the Company may become involved in lawsuits and other legal proceedings that arise in the course of business. Litigation is subject to inherent uncertainties, and it is not possible to predict the outcome of litigation with total confidence. The Company is currently not aware of any legal proceedings or potential claims against it whose outcome would be likely, individually or in the aggregate, to have a material adverse effect on the Company’s business, financial condition, operating results, or cash flows. Leases and Sublease On August 1, 2021, the Company relocated its corporate headquarters to 2222 Ponce de Leon, Floor 3, Coral Gables, FL 33134, pursuant to a lease agreement with monthly rent of approximately $11,000. The lease period was for five months. The lease agreement expired on December 31, 2021 and was renewed for the calendar year 2022 with monthly rent of approximately $6,500. The Company’s previous lease at 880 Third Avenue, 12 th Leases On June 8, 2017, the Company entered into an Amended and Restated License Agreement with Actinium Pharmaceuticals, Inc. Pursuant to the terms of the agreement, Actinium will continue to license the furniture, fixtures, equipment and tenant improvements located in its office (FFE) for a license fee of $7,529 per month until December 8, 2022. Actinium shall have at any time during the term of this agreement the right to purchase the FFE for $496,914, less any previously paid license fees. The license of FFE qualifies as a sales-type lease. At inception, the Company derecognized the underlying assets of $493,452, recognized discounted lease payments receivable of $397,049 using the discount rate of 8.38% and recognized loss on sales-type lease of fixed assets of $96,403. For the three months ended March 31, 2022 and 2021, the Company recognized lease income of approximately $1,700 and $3,300, respectively. As of March 31, 2022 and 2021, the balance of unearned interest income was approximately $2,300 and $11,500, respectively.

Other Post-Retirement Benefit P

Other Post-Retirement Benefit Plan	3 Months Ended
	Mar. 31, 2022
Retirement Benefits [Abstract]
OTHER POST-RETIREMENT BENEFIT PLAN	NOTE 8 - OTHER POST-RETIREMENT BENEFIT PLAN Relmada participates in a multiemployer 401(k) plan that permits eligible employees to contribute funds on a pretax basis subject to maximum allowed under federal tax provisions. The Company matches 100% of the first 3% of employee contributions, plus 50% of employee contributions that exceed 3% but do not exceed 5%. The employees choose an amount from various investment options for both their contributions and the Company’s matching contribution. The Company’s contribution expense was approximately $31,600 and $40,320 for the nine months ended March 31, 2022 and 2021, respectively.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 9 - SUBSEQUENT EVENTS Subsequent to March 31, 2022, 73,266 outstanding warrants were exercised for total cash proceeds of $447,723. On April 7, 2022, the Company entered into a new Open Market Sale Agreement with Jefferies, as sales agent, pursuant to which the Company may offer and sell, from time to time, through Jefferies, shares of the Company’s common stock, having an aggregate offering price of up to $100,000,000. The Company is not obligated to sell any shares under the agreement. On April 8, 2022, the Company issued a total of 484,900 common shares through this ATM equity offering facility for net proceeds of $13,284,548. Subsequent to March 31, 2022, 10,000 options were granted to a new employee with an exercise price of $25.52.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim unaudited condensed consolidated financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete consolidated financial statements. The unaudited condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements of the Company for the year ended December 31, 2021 and notes thereto contained in the Company’s Annual Report on Form 10-K.
Liquidity	Liquidity As shown in the accompanying unaudited condensed consolidated financial statements, the Company incurred negative operating cash flows of $19,429,743 for the three months ended March 31, 2022 and has an accumulated deficit of $344,812,895 from inception through March 31, 2022. Relmada has funded its past operations through equity raises and most recently in the three months ended March 31, 2022, the Company raised net proceeds of $29,583,542 from the sale of common stock through our at-the-market (ATM) equity offering, $64,800 through the exercise of options and $300,006 through the exercise of warrants. Management believes that the Company’s existing cash and cash equivalents will enable it to fund operating expenses and capital expenditure requirements for at least 12 months from the issuance of these unaudited condensed consolidated financial statements. Beyond that point management will evaluate the size and scope of any subsequent trials that will affect the timing of additional financings through public or private sales of equity or debt securities or from bank or other loans or through strategic collaboration and/or licensing agreements. Any such expenditures related to any subsequent clinical trials will not be incurred until such additional financing is raised. Further, additional financing related to subsequent clinical trials does not affect the Company’s conclusion that based on the cash on hand and the budgeted cash flow requirements, the Company has sufficient funds to maintain operations for at least 12 months from the issuance of these unaudited condensed consolidated financial statements.
Principles of Consolidation	Principles of Consolidation The unaudited condensed consolidated financial statements include the Company’s accounts and those of the Company’s wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation.
Risks and Uncertainties	Risks and Uncertainties The ongoing pandemic may adversely affect our business. Based on the Company’s current assessment, the Company does not expect any material impact on its long-term development timeline and its liquidity due to the worldwide spread of the coronavirus (COVID-19). However, the Company is actively monitoring this situation and the possible effects on its financial condition, liquidity, operations, suppliers, industry, and workforce.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates. The significant estimates are stock-based compensation expenses and recorded amounts related to income taxes.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers cash deposits and all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company’s cash deposits are held at two high-credit-quality financial institutions. The Company’s cash and cash equivalents at these institutions exceed federally insured limits. The Company’s cash balance of $44,934,376 at March 31, 2022 at these institutions exceed the federally insured limits.
Short-term Investments	Short-term Investments The Company’s investments consist entirely of mutual funds. The securities are measured at fair value based on the net asset value (NAV). Substantially all equity investments in nonconsolidated entities are measured at fair value with recurring changes recognized in earnings, except for those accounted for using equity method accounting. Changes in fair value of the securities are recorded as part of other income on the condensed consolidated statement of operations. Short term investment activity is presented in the investing activities section on the condensed consolidated statement of cash flows. Short-term investments at March 31, 2022 consisted of mutual funds with a fair value of $175,715,526.
Patents	Patents Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.
Leases	Leases The Company recognizes its leases with a term of greater than a year on the balance sheet by recording right-of-use assets and lease liabilities. Leases can be classified as either operating leases or finance leases. Operating leases will result in straight-line lease expense, while finance leases will result in front-loaded expense. The Company’s lease consists of an operating lease for office space. The Company does not recognize a lease liability or right-of-use asset on the balance sheet for short-term leases. Instead, the Company recognizes short-term lease payments as an expense on a straight-line basis over the lease term. A short-term lease is defined as a lease that, at the commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company’s financial instruments primarily include cash, short term investments, and accounts payable. Due to the short-term nature of cash and accounts payable the carrying amounts of these assets and liabilities approximate their fair value. Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability (an exit price), in an orderly transaction between market participants at the reporting date. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows: Level 1 Inputs - Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 2 Inputs - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means. Level 3 Inputs - Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity). As required by Accounting Standard Codification (ASC) Topic No. 820 - 10 Fair Value Measurement The Company’s short-term investment instruments of $175,715,526 at March 31, 2022 consist of mutual funds, bank deposits and money market funds and are classified using Level 1 inputs within the fair value hierarchy because the value is based on quoted prices in active markets. Unrealized gains and losses are recorded in the condensed consolidated statement of operations under other income. The Company recorded unrealized losses of $1,763,287 and $177,163 included in other income for the three months ended March 31, 2022 and 2021, respectively.
Income Taxes	Income Taxes The Company accounts for income taxes using the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in the tax rate is recognized in income or expense in the period that the change is effective. Tax benefits are recognized when it is probable that the deduction will be sustained. A valuation allowance is established when it is more likely than not that all or a portion of a deferred tax asset will either expire before the Company is able to realize the benefit, or that future deductibility is uncertain. As of March 31, 2022 and December 31, 2021, the Company had recognized a valuation allowance to the full extent of the Company’s net deferred tax assets since the likelihood of realization of the benefit does not meet the more likely than not threshold. The Company files a U.S. Federal income tax return and various state returns. Uncertain tax positions taken on the Company’s tax returns will be accounted for as liabilities for unrecognized tax benefits. The Company will recognize interest and penalties, if any, related to unrecognized tax benefits in general and administrative expenses in the statements of operations. There were no liabilities recorded for uncertain tax positions at March 31, 2022 and December 31, 2021. The open tax years, subject to potential examination by the applicable taxing authority, for the Company are from June 30, 2018 forward.
Research and Development	Research and Development Research and development costs primarily consist of research contracts for the advancement of product development, salaries and benefits, stock-based compensation, and consultants. The Company expenses all research and development costs in the period incurred. The Company makes an estimate of costs in relation to clinical study contracts. The Company analyzes the progress of studies, including the progress of clinical studies and phases, invoices received and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability.
Stock-Based Compensation	Stock-Based Compensation The Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the period during which an employee is required to provide service in exchange for the award - the requisite service period. The grant-date fair value of employee share options is estimated using the Black-Scholes option pricing model adjusted for the unique characteristics of those instruments.
Net Loss per Common Share	Net Loss per Common Share Basic loss per common share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted loss per common share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of options and warrants to purchase common stock. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net losses in each period. For the three months ended March 31, 2022 and 2021, the potentially dilutive securities that would be anti-dilutive due to the Company’s net loss are not included in the calculation of diluted net loss per share attributable to common stockholders. The anti-dilutive securities are as follows (in common stock equivalent shares):
Recent Accounting Pronouncements	Recent Accounting Pronouncements In November 2021, the FASB issued ASU 2021-10, “ Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance In October 2021, the FASB issued ASU 2021-08, “ Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes In May 2021, the FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)
Subsequent Events	Subsequent Events The Company’s management reviewed all material events through the date the financial statements were issued for subsequent event disclosure consideration.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Schedule of anti-dilutive securities	Three months ended March 31, March 31, Stock options 10,262,184 5,165,987 Common stock warrants 3,175,443 2,797,142 Total 13,437,627 7,963,129

Prepaid Expenses (Tables)

Prepaid Expenses (Tables)	3 Months Ended
	Mar. 31, 2022
Prepaid Expenses [Abstract]
Schedule of prepaid expenses	March 31, December 31, Insurance $ 164,600 $ 353,300 Research and Development 4,743,700 10,708,800 Legal 11,000 11,000 Other 144,700 228,400 Total $ 5,064,000 $ 11,301,500

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2022
Payables and Accruals [Abstract]
Schedule of accrued expenses	March 31, December 31, Research and development $ 3,585,200 $ 1,928,000 Professional fees 113,700 168,000 Accrued bonus 422,700 1,191,000 Accrued vacation 503,500 450,400 Other 114,200 131,000 Total $ 4,739,300 $ 3,868,400

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2022
Stockholders' Equity Note [Abstract]
Schedule of the changes in outstanding warrants	Number of Weighted Weighted Aggregate Outstanding and expected to vest at December 31, 2021 10,330,622 $ 22.52 9.00 $ 46,088,534 Granted 175,000 $ 20.35 9.84 $ - Exercised (20,000 ) $ 3.24 - $ - Forfeited (223,438 ) $ 27.22 - $ - Outstanding at March 31, 2022 10,262,184 $ 22.42 8.79 $ 78,393,636 Options exercisable at March 31, 2022 2,748,859 $ 21.56 7.42 $ 29,334,704
Schedule of the changes in outstanding warrants	Number of Weighted Outstanding and vested at December 31, 2021 3,208,777 $ 16.45 Granted - $ - Exercised (33,334 ) $ 9.00 Outstanding at March 31, 2022 3,175,443 $ 16.53 Warrants Vested at March 31, 2022 2,799,693 $ 14.40
Schedule of stock-based compensation expense	Three Three Research and development $ 1,258,400 $ 545,800 General and administrative 10,672,300 5,305,500 Total $ 11,930,700 $ 5,851,300

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Accounting Policies [Abstract]
Incurred operating costs	$ 19,429,743
Accumulated deficit	344,812,895
Net proceeds from sales	29,583,542
Amount from exercise of options	64,800
Proceeds from exercise of warrants	300,006
Cash balance	44,934,376		$ 44,443,439
Short-term investments fair value	175,715,526
Short-term investment instrument	175,715,526
Unrealized loss	$ (1,763,287)	$ 177,163

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of anti-dilutive securities - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	13,437,627	7,963,129
Stock options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	10,262,184	5,165,987
Common stock warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	3,175,443	2,797,142

Prepaid Expenses (Details) - Sc

Prepaid Expenses (Details) - Schedule of prepaid expenses - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Schedule of prepaid expenses [Abstract]
Insurance	$ 164,600	$ 353,300
Research and Development	4,743,700	10,708,800
Legal	11,000	11,000
Other	144,700	228,400
Total	$ 5,064,000	$ 11,301,500

Accrued Expenses (Details)

Accrued Expenses (Details)	Mar. 31, 2022USD ($)
Payables and Accruals [Abstract]
Accrued expenses rounded to nearest	$ 0

Accrued Expenses (Details) - Sc

Accrued Expenses (Details) - Schedule of accrued expenses - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Schedule of accrued expenses [Abstract]
Research and development	$ 3,585,200	$ 1,928,000
Professional fees	113,700	168,000
Accrued bonus	422,700	1,191,000
Accrued vacation	503,500	450,400
Other	114,200	131,000
Total	$ 4,739,300	$ 3,868,400

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)	Apr. 08, 2022	Mar. 28, 2022	Jan. 02, 2022	Jul. 12, 2021	May 15, 2020	Mar. 31, 2022	Dec. 31, 2021	May 31, 2021	Dec. 31, 2014
Stockholders' Equity (Details) [Line Items]
Issued of common stock (in Shares)						29,402,824	27,740,147
Net cash proceeds (in Dollars)	$ 13,284,548
Granting to option or stock awards (in Shares)						6,652,942		1,500,000	5,152,942
Stock options exercisable Period						10 years
Vesting period						4 years
Available shares to be issued (in Shares)						3,900,000
Future grants under the Plan (in Dollars)						$ 3,609,242
Total warrants shares (in Shares)		15,000		2,021
Exercise price per share (in Dollars per share)		$ 25.76
Term year		10 years
Vasting period		4 years
Aggregate fair value of options (in Dollars)		$ 307,845
Discount rate		2.55%
Expected life term		6 years 3 months
Expected volatility rate		98.00%
Expected dividends rate		0.00%
Unrecognized stock-based compensation expense (in Dollars)			$ 2,021,000,000			$ 129,700,000
Expected volatility rate			98.00%
Weighted average remaining service period						2 years 8 months 19 days
Aggregate intrinsic value of warrants vested (in Dollars)						$ 39,600,000
Common Stock [Member]
Stockholders' Equity (Details) [Line Items]
Issued of common stock (in Shares)						33,334
Cash exercises of warrants for proceeds (in Dollars)						$ 300,006
Common shares issued (in Shares)						20,000
Exercise of options for proceeds (in Dollars)						$ 64,800
Consultants [Member]
Stockholders' Equity (Details) [Line Items]
Total warrants shares (in Shares)			110,000
Term year			10 years
Vasting period			4 years
Aggregate fair value of options (in Dollars)			$ 1,600,000
Discount rate			1.53%
Expected life term			6 years 3 months
Expected volatility rate			2.00%
Expected dividends rate			0.00%
Consultants [Member] | Minimum [Member]
Stockholders' Equity (Details) [Line Items]
Exercise price per share (in Dollars per share)			$ 18
Consultants [Member] | Maximum [Member]
Stockholders' Equity (Details) [Line Items]
Exercise price per share (in Dollars per share)			$ 21.46
Employees and Directors [Member]
Stockholders' Equity (Details) [Line Items]
Total warrants shares (in Shares)			50,000
Exercise price per share (in Dollars per share)			$ 22.53
Term year			10 years
Vasting period			1 year
Aggregate fair value of options (in Dollars)			$ 847,583,000,000
Discount rate			1.53%
Expected life term			5 years 6 months
Expected volatility rate			96.00%
Expected dividends rate			0.00%
Jefferies LLC [Member]
Stockholders' Equity (Details) [Line Items]
Issued of common stock (in Shares)						1,609,343
Aggregate of offering price (in Dollars)					$ 75,000,000
Net cash proceeds (in Dollars)						$ 29,583,542

Stockholders' Equity (Details)

Stockholders' Equity (Details) - Schedule of changes in options outstanding - Options [Member]	3 Months Ended
	Mar. 31, 2022USD ($)$ / sharesshares
Stockholders' Equity (Details) - Schedule of changes in options outstanding [Line Items]
Number of Options, Outstanding and expected to vest, Beginning balance | shares	10,330,622
Weighted Average Exercise Price Per Share, Outstanding and expected to vest - Beginning balance | $ / shares	$ 22.52
Weighted Average Remaining Contractual Term (Years), Beginning balance	9 years
Aggregate Intrinsic Value, Outstanding and expected to vest - Beginning balance | $	$ 46,088,534
Number of Options, Granted | shares	175,000
Weighted Average Exercise Price Per Share, Granted | $ / shares	$ 20.35
Weighted Average Remaining Contractual Term (Years), Granted	9 years 10 months 2 days
Number of Options, Exercised | shares	(20,000)
Weighted Average Exercise Price Per Share, Exercised | $ / shares	$ 3.24
Weighted Average Remaining Contractual Term (Years), Exercised
Aggregate Intrinsic Value, Outstanding and expected to vest, Exercised | $
Number of Options, Forfeited | shares	(223,438)
Weighted Average Exercise Price Per Share, Forfeited | $ / shares	$ 27.22
Weighted Average Remaining Contractual Term (Years), Forfeited
Aggregate Intrinsic Value, Outstanding and expected to vest, Forfeited | $
Number of Options, Outstandin and expected to vest, Ending balance | shares	10,262,184
Weighted Average Exercise Price Per Share, Outstandin and expected to vest, Ending balance | $ / shares	$ 22.42
Weighted Average Remaining Contractual Term (Years), Ending balance	8 years 9 months 14 days
Aggregate Intrinsic Value, Outstandin and expected to vest, Ending balance | $	$ 78,393,636
Number of Options, Options exercisable | shares	2,748,859
Weighted Average Exercise Price Per Share, Options exercisable | $ / shares	$ 21.56
Weighted Average Remaining Contractual Term (Years), Options exercisable	7 years 5 months 1 day
Aggregate Intrinsic Value, Options exercisable | $	$ 29,334,704

Stockholders' Equity (Details_2

Stockholders' Equity (Details) - Schedule of the changes in outstanding warrants	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Schedule of the changes in outstanding warrants [Abstract]
Number of Shares, Outstanding and vested, Beginning balance | shares	3,208,777
Weighted Average Exercise Price Per Share, Outstanding and vested, Beginning balance | $ / shares	$ 16.45
Number of Shares, Granted | shares
Weighted Average Exercise Price Per Share, Granted | $ / shares
Number of Shares, Exercised | shares	(33,334)
Weighted Average Exercise Price Per Share, Exercised | $ / shares	$ 9
Number of Shares, Outstanding and vested, Ending balance | shares	3,175,443
Weighted Average Exercise Price Per Share, Outstanding and vested, Ending balance | $ / shares	$ 16.53
Number of Shares, Warrants Vested | shares	2,799,693
Weighted Average Exercise Price Per Share, Warrants Vested | $ / shares	$ 14.4

Stockholders' Equity (Details_3

Stockholders' Equity (Details) - Schedule of stock-based compensation expense - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 11,930,700	$ 5,851,300
Research and development [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	1,258,400	545,800
General and administrative [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 10,672,300	$ 5,305,500

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	Mar. 06, 2021	Mar. 06, 2020	Dec. 31, 2020	Mar. 31, 2022
Dr. Vitolo [Member]
Related Party Transactions (Details) [Line Items]
severance fees		$ 200,000
Exercise price		$ 126,562
Attorneys fees	$ 45,000
Dr.Wessel [Member]
Related Party Transactions (Details) [Line Items]
severance fees			$ 237,500
Accrued vacation fees				$ 28,940

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	Jul. 16, 2021	Jun. 08, 2017	Mar. 31, 2022	Mar. 31, 2021
Commitments and Contingencies (Details) [Line Items]
Pay licensor			$ 45,000
License agreement, description	the Company paid Arbormentis, LLC an upfront fee of $12.7 million, consisting of a mix of cash and warrants to purchase the Company’s common stock, in addition to potential milestone payments totaling up to approximately $160 million related to pre-specified development and commercialization milestones. Arbormentis, LLC is also eligible to receive a low single digit royalty on net sales of any commercialized therapy resulting from this agreement. The license agreement is terminable by the Company but is perpetual and not terminable by the licensor absent material breach of its terms by the Company.
Lease period			5 months
Rent			$ 6,500
Lease expense			19,500	$ 15,900
Lease income			1,700	3,300
Unearned interest income			$ 2,300	$ 11,500
Licensing Agreements [Member]
Commitments and Contingencies (Details) [Line Items]
Description of rights granted to license agreement			In consideration of the rights granted to Relmada under the License Agreement, Relmada paid the Licensor an upfront, non-refundable license fee of $180,000. Additionally, Relmada will pay Licensor $45,000 every three months until the earliest to occur of the following events: (i) the first commercial sale of a licensed product anywhere in the world, (ii) the expiration or invalidation of the last to expire or be invalidated of the patent rights anywhere in the world, or (iii) the termination of the License Agreement. Relmada will also pay Licensor tiered royalties with a maximum rate of 2%, decreasing to 1.75%, and 1.5% in certain circumstances, on net sales of licensed products covered under the License Agreement. Relmada will also pay Licensor tiered payments up to a maximum of 20%, and decreasing to 17.5%, and 15% in certain circumstances, of all consideration received by Relmada for sublicenses granted under the License Agreement.
Licensing Agreements [Member] | Minimum [Member]
Commitments and Contingencies (Details) [Line Items]
Term of licensing agreement			15 years
Licensing Agreements [Member] | Maximum [Member]
Commitments and Contingencies (Details) [Line Items]
Term of licensing agreement			20 years
FFE [Member]
Commitments and Contingencies (Details) [Line Items]
Description of lease agreement		Actinium will continue to license the furniture, fixtures, equipment and tenant improvements located in its office (FFE) for a license fee of $7,529 per month until December 8, 2022. Actinium shall have at any time during the term of this agreement the right to purchase the FFE for $496,914, less any previously paid license fees. The license of FFE qualifies as a sales-type lease. At inception, the Company derecognized the underlying assets of $493,452, recognized discounted lease payments receivable of $397,049 using the discount rate of 8.38% and recognized loss on sales-type lease of fixed assets of $96,403.
Wonpung [Member] | Licensing Agreements [Member]
Commitments and Contingencies (Details) [Line Items]
License agreement			$ 1,500,000
Net sales rate			12.00%
Wonpung [Member] | Business Combination [Member] | Licensing Agreements [Member]
Commitments and Contingencies (Details) [Line Items]
Business acquisition, description			(A) royalty payments up to 2% on net sales of licensed products that are not sold by sublicensee and (B) on each and every sublicense earned royalty payment received by licensee from its sublicensee on sales of license product by sublicensee, the higher of (i) 20% of the royalties received by licensee; or (ii) up to 2% of net sales of sublicensee. The Company will also make milestone payments of up to $4 or $2 million, for the first commercial sale of product in the field that has a single active pharmaceutical ingredient, and for the first commercial sale of product in the field of product that has more than one active pharmaceutical ingredient, respectively. As of March 31, 2022, the Company has not generated any revenue related to this license agreement.

Other Post-Retirement Benefit_2

Other Post-Retirement Benefit Plan (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Retirement Benefits [Abstract]
Employee contributions, description	The Company matches 100% of the first 3% of employee contributions, plus 50% of employee contributions that exceed 3% but do not exceed 5%.
Employee contribution expense	$ 31,600	$ 40,320

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	Apr. 08, 2022	Mar. 31, 2022	Apr. 07, 2022
Subsequent Events (Details) [Line Items]
Outstanding warrants were exercised		73,266
Total cash proceeds		$ 447,723
Total of common shares	484,900
Net proceeds	$ 13,284,548
Options were granted		10,000
Exercise price		$ 25.52
Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Aggregate offering price			$ 100,000,000